Literature DB >> 33203729

IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases.

Rosalie G Hoyle1,2, Huiqun Wang1, Yana Cen1,2, Yan Zhang1,2,3, Jiong Li4,2,3,5,6.   

Abstract

Epigenetic activation of Wnt/β-catenin signaling plays a critical role in Wnt-induced tumorigenesis, notably in colorectal cancers. KDM3 and KDM4 histone demethylases have been reported to promote oncogenic Wnt signaling through demethylation of H3K9 on Wnt target gene promoters and are suggested to be potential therapeutic targets. However, potent inhibitors for these regulators are still not available. In addition, which family is most responsible for activation of Wnt target genes and Wnt-induced oncogenesis is not well documented, specifically in colorectal cancer. In this study, we characterized the functional redundancy and differences between KDM3 and KDM4 in regard to regulating Wnt signaling. Our data suggest that KDM3 may play a more essential role than KDM4 in regulating oncogenic Wnt signaling in human colorectal cancer. We also identified that IOX1, a known histone demethylase inhibitor, significantly suppresses Wnt target gene transcription and colorectal cancer tumorigenesis. Mechanistically, IOX1 inhibits the enzymatic activity of KDM3 by binding to the Jumonji C domain and thereby preventing the demethylation of H3K9 on Wnt target gene promoters. Taken together, our data not only identified the critical mechanisms by which IOX1 suppressed Wnt/β-catenin signaling and colorectal cancer tumorigenesis through inhibition of KDM3, but also suggested that IOX1 may represent an attractive small molecule lead for future drug design and discovery. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33203729      PMCID: PMC7790990          DOI: 10.1158/1535-7163.MCT-20-0328

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.009


  46 in total

Review 1.  Wnt/beta-catenin signaling: components, mechanisms, and diseases.

Authors:  Bryan T MacDonald; Keiko Tamai; Xi He
Journal:  Dev Cell       Date:  2009-07       Impact factor: 12.270

2.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

Review 3.  Targeting the Wnt signaling pathway in colorectal cancer.

Authors:  Masaaki Sawa; Mari Masuda; Tesshi Yamada
Journal:  Expert Opin Ther Targets       Date:  2015-10-06       Impact factor: 6.902

4.  JMJD2B promotes epithelial-mesenchymal transition by cooperating with β-catenin and enhances gastric cancer metastasis.

Authors:  Li Zhao; Wenjuan Li; Wen Zang; Zhifang Liu; Xia Xu; Han Yu; Qing Yang; Jihui Jia
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

5.  Histone Lysine Demethylases of JMJD2 or KDM4 Family are Important Epigenetic Regulators in Reward Circuitry in the Etiopathology of Depression.

Authors:  Salil Saurav Pathak; Swati Maitra; Sumana Chakravarty; Arvind Kumar
Journal:  Neuropsychopharmacology       Date:  2016-10-06       Impact factor: 7.853

Review 6.  Targeting cancer stem cells to suppress acquired chemotherapy resistance.

Authors:  S J Vidal; V Rodriguez-Bravo; M Galsky; C Cordon-Cardo; J Domingo-Domenech
Journal:  Oncogene       Date:  2013-10-07       Impact factor: 9.867

7.  Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication.

Authors:  Sumana Chakravarty; Priya Jhelum; Unis Ahmad Bhat; Wenson D Rajan; Swati Maitra; Salil S Pathak; Anant B Patel; Arvind Kumar
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-09-21       Impact factor: 5.187

8.  Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.

Authors:  Shohei Hamada; Tae-Dong Kim; Takayoshi Suzuki; Yukihiro Itoh; Hiroki Tsumoto; Hidehiko Nakagawa; Ralf Janknecht; Naoki Miyata
Journal:  Bioorg Med Chem Lett       Date:  2009-03-26       Impact factor: 2.823

9.  Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors.

Authors:  Oliver N F King; Xuan Shirley Li; Masaaki Sakurai; Akane Kawamura; Nathan R Rose; Stanley S Ng; Amy M Quinn; Ganesha Rai; Bryan T Mott; Paul Beswick; Robert J Klose; Udo Oppermann; Ajit Jadhav; Tom D Heightman; David J Maloney; Christopher J Schofield; Anton Simeonov
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

10.  Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling.

Authors:  Andreas Herbst; Vindi Jurinovic; Stefan Krebs; Susanne E Thieme; Helmut Blum; Burkhard Göke; Frank T Kolligs
Journal:  BMC Genomics       Date:  2014-01-28       Impact factor: 3.969

View more
  3 in total

1.  Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.

Authors:  Jing Liu; Zhihao Zhao; Nasha Qiu; Quan Zhou; Guowei Wang; Haiping Jiang; Ying Piao; Zhuxian Zhou; Jianbin Tang; Youqing Shen
Journal:  Nat Commun       Date:  2021-04-23       Impact factor: 14.919

Review 2.  Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response.

Authors:  Kai Wang; Chao Yang; Haibin Li; Xiaoyan Liu; Meiling Zheng; Zixue Xuan; Zhiqiang Mei; Haiyong Wang
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 7.561

Review 3.  Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications.

Authors:  Rachel Shi; Chengheng Liao; Qing Zhang
Journal:  Cells       Date:  2021-03-19       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.